Originally founded in 1980 as AMGen (Applied Molecular Genetics), Amgen pioneered the development of innovative products based on advances in recombinant DNA and molecular biology. More than a decade ago, Amgen introduced two of the first biologically derived human therapeutics (Epoetin alfa and Filgrastim). These products have improved the lives of hundreds of thousands of patients suffering from conditions related to chronic kidney disease and cancer.

Today, Amgen is a Fortune 500 company whose business has expanded to serve patients around the world in supportive cancer care and the treatment of anaemia, rheumatoid arthritis, and other autoimmune diseases such as psoriatic arthritis and ankylosing spondylitis. We continue to sustain a culture rooted in biotechnology entrepreneurialism and innovation. As a science-based and patient-focused organization, Amgen will follow the science wherever it may lead, to best treat serious illness.